Roivant Sciences shares jump after positive mid-stage trial results
Roivant Sciences shares rose 22% to $42.68 after the company disclosed positive results from a mid-stage trial evaluating its pulmonary hypertension treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.